[Public Notice+] Woojin B&G Obtains Patent Related to Swine Atrophic Rhinitis Vaccine

[Asia Economy Reporter Eunmo Koo] Woojin B&G announced on the 28th through a public disclosure that it has developed a vaccine for swine dysentery and obtained a patent.

The patent is titled "Vaccine composition for the treatment or prevention of swine dysentery" and relates to the development of a vaccine to prevent swine dysentery, a major infectious disease causing inflammation and bloody diarrhea in the swine large intestine. It is an oral vaccine containing antigen proteins, including the cell wall protein of Brachyspira hyodysenteriae and M cell-targeting peptides, encapsulated in an ileum-targeted mucosal adhesive polymer carrier.

A Woojin B&G official explained, "Oral vaccines not only reduce stress caused by injections but also activate mucosal immune responses, producing secretory antibodies such as IgA that neutralize pathogens and prevent their entry into the body, thereby defending against infections at an early stage. Oral vaccines are more effective than injectable vaccines in directly blocking and preventing waterborne infectious diseases caused by bacteria and viruses such as dysentery and cholera at the infection route."

Oral vaccines generally tend to lose their efficacy during transportation, and even if safely delivered to the small intestine, they face challenges in absorption efficiency at the small intestinal mucosal layer, limiting their use. However, the oral vaccine developed in this patent uses an ileum-targeted, controlled-release, mucosal adhesive HPMCP polymer carrying the swine dysentery antigen protein (BmpB) conjugated with an M cell-targeting peptide moiety, making it convenient and effective for use.

This content was produced with the assistance of AI translation services.